Proliferative Diabetic Retinopathy (PDR) Market Size, Share, Trends, Growth, Countries And Industry Forecast To 2033

The proliferative diabetic retinopathy (pdr) market size has grown rapidly in recent years. It will grow from $2.16 billion in 2023 to $2.42 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.

The proliferative diabetic retinopathy (pdr) market size is expected to see rapid growth in the next few years. It will grow to $3.62 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (ai) for early diagnosis, gene therapy advancements, advanced retinal imaging.

Market Overview -
Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Rising Diabetes Prevalence Boosts Growth In The Proliferative Diabetic Retinopathy (PDR) Market
The rising prevalence of diabetes is expected to propel the growth of the proliferative diabetic retinopathy (PDR) market going forward. Diabetes is a chronic medical condition characterized by elevated glucose (sugar) levels in the blood. Diabetes is the leading cause of proliferative diabetic retinopathy disease, which can be treated by various methods that prevent further damage to the retina and preserve vision. For instance, in 2021, according to the International Diabetes Federation (IDF), a Belgium-based organization, 537 million adults aged between 20-79 are suffering from diabetes (1 in 10 people) and this number is expected to reach about 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes drives the proliferative diabetic retinopathy (PDR) market.

Competitive Landscape -
Major players in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Innovative Therapies Revolutionize Proliferative Diabetic Retinopathy Treatment Landscape
Major companies operating in the proliferative diabetic retinopathy market continuously focus on developing novel therapies to enhance treatment effectiveness, reduce treatment burden and improve patient outcomes. For example, in June 2022, Biogen, a US-based biotechnology company and Samsung Bioepis, a South Korea-based biotech company, introduced Byooviz (ranibizumab-nuna), the first ophthalmology biosimilar in the US. These products are used to treat patients with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD) and choroidal neovascularization.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Key Segments -
The proliferative diabetic retinopathy (pdr) market covered in this report is segmented -
1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
3) By Application: Hospitals; Clinics; Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.